Baltimore-based CraniUS Therapeutics has received an initial USD 1.1 million award through the NIH Blueprint MedTech Optimizer Program, with the potential to access up to USD 4 million in total funding, to advance its skull-embedded NeuroPASS drug delivery platform toward a first-in-human study in recurrent glioblastoma.
The award is notable because blood-brain barrier penetration remains one of the most persistent obstacles in neuro-oncology and CNS drug development broadly. Recurrent glioblastoma carries a median overall survival of approximately six to nine months, and systemic therapies consistently fail to achieve therapeutic concentrations in brain tissue. NeuroPASS is a refillable implant embedded within the skull that delivers therapy directly into the brain parenchyma. A concealed refill port enables repeated outpatient administration, potentially supporting chronic dosing while minimizing systemic exposure. The device is intended to reduce systemic exposure while enabling chronic dosing — a combination that distinguishes it from single-administration intracranial approaches and convection-enhanced delivery systems, which have not demonstrated durable clinical benefit in glioblastoma.
The NIH Blueprint MedTech Optimizer Program, funded by the National Institute of Neurological Disorders and Stroke and administered by the National Institute of Biomedical Imaging and Bioengineering, provides non-dilutive support specifically for neurotechnology devices. CraniUS, founded in 2021, will use the funding to advance engineering, manufacturing, preclinical, and regulatory activities ahead of clinical evaluation. The grant follows a Series B round worth USD 20 million closed in January 2026. The company has indicated that while recurrent glioblastoma is the lead indication, the platform is designed to accommodate biologics, gene therapies, and cellular therapies across CNS indications.
Competitors in the intracranial drug delivery space include convection-enhanced delivery catheter systems and implantable pump technologies, though none has achieved broad clinical adoption in glioblastoma. The NeuroPASS approach, leveraging the temporal skull space for long-term implantation, represents a structural differentiation from catheter-based systems, though clinical validation remains ahead.